Citadel Advisors
RLMD icon

Citadel Advisors’s Relmada Therapeutics RLMD Stock Holding History

Citadel Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$169K Sell
24,300
-10,800
-31% -$51.1K ﹤0.01% 11580
2025
Q4 		$170K Buy
35,100
+16,800
+92% +$56.3K ﹤0.01% 11189
2025
Q3 		$36.8K Buy
+18,300
New +$17.6K ﹤0.01% 12327
2025
Q1 		– Sell
-129,800
Closed -$67.5K – 15405
2024
Q4 		$67.5K Buy
129,800
+62,700
+93% +$153K ﹤0.01% 12027
2024
Q3 		$217K Buy
67,100
+24,100
+56% +$78K ﹤0.01% 9976
2024
Q2 		$129K Buy
43,000
+3,300
+8% +$11.9K ﹤0.01% 10554
2024
Q1 		$185K Buy
39,700
+13,000
+49% +$62.6K ﹤0.01% 10443
2023
Q4 		$111K Sell
26,700
-7,300
-21% -$21.6K ﹤0.01% 10808
2023
Q3 		$102K Sell
34,000
-61,800
-65% -$184K ﹤0.01% 10869
2023
Q2 		$236K Sell
95,800
-13,400
-12% -$37K ﹤0.01% 9530
2023
Q1 		$247K Sell
109,200
-133,100
-55% -$459K ﹤0.01% 9783
2022
Q4 		$846K Sell
242,300
-218,300
-47% -$1.92M ﹤0.01% 7139
2022
Q3 		$17.1M Buy
460,600
+328,200
+248% +$9.09M ﹤0.01% 2058
2022
Q2 		$2.51M Buy
132,400
+78,900
+147% +$1.72M ﹤0.01% 5094
2022
Q1 		$1.44M Buy
53,500
+15,300
+40% +$316K ﹤0.01% 6819
2021
Q4 		$861K Sell
38,200
-23,200
-38% -$516K ﹤0.01% 8325
2021
Q3 		$1.61M Buy
61,400
+39,400
+179% +$1.05M ﹤0.01% 6912
2021
Q2 		$704K Sell
22,000
-5,400
-20% -$188K ﹤0.01% 9234
2021
Q1 		$965K Buy
27,400
+12,900
+89% +$451K ﹤0.01% 8207
2020
Q4 		$465K Sell
14,500
-5,200
-26% -$179K ﹤0.01% 8277
2020
Q3 		$741K Buy
+19,700
New +$761K ﹤0.01% 6583

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Citadel Advisors's RLMD Position: Q1 2026 in Review

Citadel Advisors sold out of Relmada Therapeutics (RLMD) in Q1 2026, closing a stake of 28,063 shares — an estimated $133K sold.

Citadel Advisors first reported a position in RLMD in Q4 2019 and held it in 19 quarters. The position peaked at $34.5M in Q3 2022. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Citadel Advisors reported no remaining Relmada Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 28,063 Relmada Therapeutics shares in Q1 2026, an estimated $133K.
  • Citadel Advisors first reported a position in Relmada Therapeutics in Q4 2019 and held it in 19 quarters.
  • Citadel Advisors's Relmada Therapeutics position peaked at $34.5M in Q3 2022.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.